Acumen Pharmaceuticals ABOS Earnings Preview: Analysts Anticipate $-0.53 EPS, Stock Down 48.38% Over Last 52 Weeks

Acumen Pharmaceuticals is set to release its quarterly earnings report on 2025-08-12. Analysts expect EPS of $-0.53. The company's past performance shows that it has beaten EPS estimates in the previous earnings release, leading to a 6.67% drop in share price. Shares are currently trading at $1.36, down 48.38% over the last 52 weeks.

Acumen Pharmaceuticals ABOS (NASDAQ: ABOS) is scheduled to release its quarterly earnings report on Tuesday, August 12, 2025. Analysts expect the company to report an earnings per share (EPS) of $-0.53. This announcement comes after a series of mixed earnings reports and significant stock price fluctuations.

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, has a history of beating EPS estimates. In its previous earnings release, the company exceeded expectations by $0.07, leading to a 6.67% drop in the share price the following trading session. This trend highlights the volatility that can accompany earnings releases, with positive surprises often resulting in share price declines due to high expectations.

Shares of Acumen Pharmaceuticals are currently trading at $1.36, down 48.38% over the last 52 weeks. The company's stock has been on a downward trajectory, with analysts expecting an EPS of $-0.54 for the current quarter. Despite this, Citigroup has initiated coverage on Acumen Pharmaceuticals with a "buy" rating and a price target of $4.00 per share, suggesting a potential upside for the stock.

Investors should be aware that market reactions are often driven by guidance rather than earnings performance alone. The company's focus on advancing targeted immunotherapy drug candidate sabirnetug (ACU193) for the treatment of Alzheimer's disease could provide insights into future growth prospects. However, the stock's recent performance indicates a level of uncertainty and volatility that investors must consider.

To stay informed about Acumen Pharmaceuticals' earnings releases, investors can track their earnings calendar on Benzinga's site. Additionally, institutional investors such as AQR Capital Management LLC have shown interest in the company, buying new positions in its stock.

References:
[1] https://www.benzinga.com/insights/earnings/25/08/47041700/acumen-pharmaceuticalss-earnings-a-preview
[2] https://www.marketbeat.com/instant-alerts/acumen-pharmaceuticals-abos-expected-to-announce-earnings-on-tuesday-2025-08-05/